Small Cell Lung Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Small Cell Lung Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 4 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in BrazilNCT06008353observationalDemographic Characteristics of the Cohort | — | Active, not recruiting | 2026-08-31 | in 11 d | 2024-12-19 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| IDYA | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-07-13 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AMGN | Amgen | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)NCT03319940Number of participants with dose limiting toxicities (DLT) for all indications | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2025-11-19 |
| PFE | Pfizer | PF-07104091 as a Single Agent and in Combination TherapyNCT04553133Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle | Phase 2 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-05-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Small Cell Lung Cancer
most recently updated first139 studies match. Showing the first 100 of 139 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BOLD | Boundless Bio, Inc. | $65M | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsNCT05827614Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825 | Phase 1 | Terminatedsponsor's stated reason: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal. | Drug: BBI-355, Erlotinib, Futibatinib, BBI-825 | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer | 85 | 2023-03-24 | 2026-03-17actual | — | 2026-08-19 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerNCT07365241Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR) | Phase 3 | Recruiting | Drug: ABBV-706, Topotecan, Topotecan, Lurbinectedin, Amrubicin | Small Cell Lung Cancer | 531 | 2026-07-02 | Sep 2030 | ≤ 1,502 d | 2026-08-19 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung CancerNCT07325136Number of participants with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986525, Pumitamig | Relapsed/Refractory Small Cell Lung Cancer | 240 | 2026-02-03 | 2029-04-23 | in 977 d | 2026-08-18 |
| PBYI | Puma Biotechnology, Inc. | $477M | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerNCT06095505Objective response rate (ORR) within biomarker-defined subgroup | Phase 2 | Recruiting | Drug: Alisertib | Small Cell Lung Cancer | 120 | 2024-02-08 | 2027-10-30 | in 436 d | 2026-08-17 |
| AMGN | Amgen | $229.9B | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCNCT06745323Proportion of participants with confirmed objective response to Tarlatamab | Phase 2 | Active, not recruiting | Drug: Tarlatamab | Small Cell Lung Cancer (SCLC) | 252 | 2025-02-26 | 2029-05-10 | in 994 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerNCT07226999Phase 2: Confirmed Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] based on the investigator's assessment | Phase 2/3 | Recruiting | Drug: PF-08634404, Chemotherapy · Biological: Atezolizumab | Small Cell Lung Cancer (SCLC) | 550 | 2025-12-09 | 2030-06-14 | in 1,394 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerNCT07476287Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) | Phase 2 | Recruiting | Drug: PF-08634404, Chemotherapy | Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung, Small Cell Cancer Of The Lung | 40 | 2026-07-02 | 2028-03-19 | in 577 d | 2026-08-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276Overall Survival (OS) | Phase 3 | Recruiting | Biological: BMS-986489 (BMS-986012+Nivolumab), Atezolizumab · Drug: Carboplatin, Etoposide | Extensive-Stage Small Cell Lung Cancer | 530 | 2025-02-25 | 2028-04-06 | in 595 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerNCT07155174Number of Participants with Adverse Events (AE)s | Phase 2 | Recruiting | Drug: ABBV-706, Atezolizumab, Etoposide, Carboplatin, Carboplatin, Lurbinectedin | Small Cell Lung Cancer | 180 | 2025-11-25 | Apr 2029 | ≤ 984 d | 2026-08-14 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834Overall Survival (OS) | Phase 3 | Recruiting | Drug: Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available) | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 695 | 2025-04-04 | Oct 2029 | ≤ 1,168 d | 2026-08-12 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2020-10-29 | 2026-08-15 | — | 2026-08-10 |
| AMGN | Amgen | $229.9B | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)NCT07531095Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: ZL-1310, Tarlatamab, Durvalumab | Small Cell Lung Cancer | 160 | 2026-04-21 | 2028-05-21 | in 640 d | 2026-08-07 |
| 4568.T | Daiichi Sankyo | $31.7B | Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung CancerNCT07535359expanded access | — | Available | Drug: Ifinatamab Deruxtecan | SCLC, Extensive-stage Small Cell Lung Cancer | — | — | — | — | 2026-08-07 |
| 051910.KS | LG Chem | $13.7B | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNCT07752875Phase 1: Number of participants with dose-limiting toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: LG00313112 | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Pancreatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumor | 250 | 2026-12-01 | 2032-10-31 | in 2,264 d | 2026-08-07 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06203210Overall Survival (OS) | Phase 3 | Recruiting | Drug: Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin | Small Cell Lung Cancer | 540 | 2024-05-21 | 2028-01-30 | in 528 d | 2026-08-06 |
| PFE | Pfizer | $155.3B | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD) | Phase 1 | Recruiting | Drug: Mervometostat (PF-06821497), Enzalutamide, Itraconazole | Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL) | 453 | 2018-04-17 | 2028-04-20 | in 609 d | 2026-07-29 |
| AZN | AstraZeneca | — | Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.NCT06992609To describe the safety profile of durvalumab for patients with LS-SCLC who have not progressed following CRT. | Phase 3 | Active, not recruiting | Drug: Durvalumab | Small Cell Lung Carcinoma | 68 | 2025-09-15 | 2029-06-30 | in 1,045 d | 2026-07-27 |
| BNTX | BioNTech SE | — | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355Overall survival (OS) | Phase 3 | Recruiting | Drug: Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated) | Extensive-stage Small-cell Lung Cancer | 621 | 2025-02-03 | Dec 2028 | ≤ 864 d | 2026-07-24 |
| AMGN | Amgen | $229.9B | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)NCT05060016Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Phase 2 | Active, not recruiting | Drug: Tarlatamab | Relapsed/Refractory Small Cell Lung Cancer | 222 | 2021-12-01 | 2027-12-30 | in 497 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsNCT06131840Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma | 914 | 2023-11-20 | 2029-09-12 | in 1,119 d | 2026-07-22 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCNCT07459634Investigator assessed PFS rate | Phase 2 | Recruiting | Drug: Lurbinectedin, Durvalumab | Extensive-stage Small-cell Lung Cancer | 50 | 2026-08-30 | 2028-01-31 | in 529 d | 2026-07-20 |
| AZN | AstraZeneca | — | Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)NCT03043872results2021-03-04Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP | Phase 3 | Active, not recruiting | Drug: Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide | Small Cell Lung Carcinoma Extensive Disease | 987 | 2017-03-27 | 2020-01-27actual | — | 2026-07-16 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2023-11-01 | 2027-02-28 | in 192 d | 2026-07-16 |
| AMGN | Amgen | $229.9B | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128Overall Survival (OS) | Phase 3 | Recruiting | Drug: Tarlatamab, Durvalumab, Carboplatin, Etoposide | Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | 330 | 2025-08-18 | 2029-01-04 | in 868 d | 2026-07-16 |
| AZN | AstraZeneca | — | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.NCT02734004results2023-10-13Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12 | Phase 1/2 | Active, not recruiting | Drug: Olaparib, MEDI4736, Bevacizumab | Ovarian, Breast, SCLC, Gastric Cancers | 264 | 2016-03-17 | 2021-09-17actual | — | 2026-07-14 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Drug: IDE-161, Pembrolizumab | Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC | 216 | 2023-04-18 | Oct 2026 | ≤ 72 d | 2026-07-13 |
| AMGN | Amgen | $229.9B | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of TreatmentNCT06502977results2026-04-15Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | Phase 2 | Active, not recruiting | Drug: Tarlatamab | Extensive Stage Small Cell Lung Cancer | 32 | 2024-08-27 | 2025-03-28actual | — | 2026-07-09 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerNCT07174583Part 1A: Safety and Tolerability of IDE849 (Monotherapy) | Phase 1/2 | Recruiting | Drug: IDE849, durvalumab, IDE161, Carboplatin | Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3 | 262 | 2025-10-14 | Jul 2029 | ≤ 1,076 d | 2026-07-09 |
| AZN | AstraZeneca | — | Study of AZD2811 + Durvalumab in ES-SCLCNCT04745689results2025-03-27Maintenance Participants Alive and Progression Free (APF12) Per RECIST 1.1 [Efficacy] | Phase 2 | Active, not recruiting | Drug: Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide | Small-Cell Lung Cancer | 31 | 2021-02-23 | 2022-06-18actual | — | 2026-07-06 |
| AMGN | Amgen | $229.9B | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)NCT06598306Number of Participants with Dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: Tarlatamab | Extensive Stage Small Cell Lung Cancer | 220 | 2024-10-07 | 2027-04-24 | in 247 d | 2026-06-26 |
| ONC | BeOne Medicines | $545.6B | A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)NCT07652736observationalTime from Diagnosis to First Dose | — | Recruiting | Drug: Tislelizumab | Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | 440 | 2026-06-05 | 2027-11-15 | in 452 d | 2026-06-25 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4175408 in Participants With Advanced CancerNCT07046923Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408 | Phase 1 | Recruiting | Drug: LY4175408, Pembrolizumab, Carboplatin, Cisplatin | Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer | 240 | 2025-07-28 | Jul 2030 | ≤ 1,441 d | 2026-06-23 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerNCT04702880results2026-06-17Number of Participants With Adverse Events | Phase 2 | Completed | Biological: BMS-986012, Nivolumab · Drug: Carboplatin, Etoposide | Extensive-stage Small Cell Lung Cancer | 135 | 2021-03-17 | 2025-05-22actual | — | 2026-06-17 |
| AZN | AstraZeneca | — | A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.NCT05683977observationalThe time to first line treatment discontinuation (TTD). | — | Active, not recruiting | Drug: durvalumab | Small Cell Lung Carcinoma | 254 | 2022-11-14 | 2027-03-01 | in 193 d | 2026-06-16 |
| TEM | Tempus AI | $8.6B | Tempus Small Cell Lung Cancer Observational Study (Sculptor)NCT05257551observationalTo determine if tumor tissue transcriptional subtypes can be detected | — | Recruiting | Other: Observation | Small Cell Lung Cancer | 200 | 2022-07-13 | Mar 2029 | ≤ 954 d | 2026-06-15 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsNCT07517198Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: EXS74539 | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC) | 40 | 2026-04-13 | Mar 2029 | ≤ 954 d | 2026-06-10 |
| JANX | Janux Therapeutics | $1.0B | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesNCT05783622Incidence of Dose Limiting Toxicities (DLT) | Phase 1 | Active, not recruiting | Drug: JANX008 | Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer | 130 | 2023-04-19 | 2026-07-31 | — | 2026-06-01 |
| AMGN | Amgen | $229.9B | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)NCT07037758Number of Participants with Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: Tarlatamab, AB248 | Extensive Stage Small Cell Lung Cancer | 380 | 2025-09-16 | 2028-03-18 | in 576 d | 2026-05-29 |
| MOLN | Molecular Partners AG | — | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsNCT07278479To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279 | Phase 1/2 | Recruiting | Drug: [212Pb]Pb-MP0712 · Other: [203Pb]Pb-MP0712 | Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC | 138 | 2026-05-18 | Sep 2028 | ≤ 772 d | 2026-05-22 |
| AMGN | Amgen | $229.9B | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)NCT06898957Number of Participants Experiencing Dose-limiting toxicities (DLTs) | Phase 1 | Active, not recruiting | Drug: YL201, Tarlatamab, Durvalumab | Small Cell Lung Cancer | 29 | 2025-05-16 | 2031-06-23 | in 1,768 d | 2026-05-20 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung CancerNCT06799286Number of participants with adverse events (AEs) | Phase 1 | Active, not recruiting | Drug: BMS-986489 | Small Cell Lung Carcinoma | 10 | 2025-05-07 | 2027-05-26 | in 279 d | 2026-05-13 |
| PFE | Pfizer | $155.3B | PF-07104091 as a Single Agent and in Combination TherapyNCT04553133Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle | Phase 2 | Active, not recruiting | Drug: PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6) | Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer | 157 | 2020-09-16 | 2026-12-31 | in 133 d | 2026-05-06 |
| AMGN | Amgen | $229.9B | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)NCT06117774PFS as Determined by BICR | Phase 3 | Active, not recruiting | Drug: Tarlatamab, Placebo | Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | 404 | 2024-02-20 | 2030-04-20 | in 1,339 d | 2026-04-29 |
| CMPX | Compass Therapeutics | $430M | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced MalignanciesNCT03881488Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities | Phase 1 | Completed | Drug: CTX-471, Pembrolizumab (KEYTRUDA®) | Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer | 100 | 2019-05-17 | 2025-05-21actual | — | 2026-04-17 |
| BNTX | BioNTech SE | — | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With ChemotherapyNCT06449209Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-related serious adverse events (SAEs) and treatment-related treatment emergent SAEs | Phase 2 | Active, not recruiting | Drug: BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan | Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer | 110 | 2024-08-05 | Jun 2027 | ≤ 314 d | 2026-04-17 |
| PBYI | Puma Biotechnology, Inc. | $477M | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)NCT07465757Percentage of Participants with Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) | Phase 2 | Not yet recruiting | Drug: Alisertib, Alisertib, Alisertib, Alisertib, Alisertib, Paclitaxel | Small Cell Lung Cancer ( SCLC ) | 50 | 2026-09-30 | 2028-03-31 | in 589 d | 2026-03-12 |
| AMGN | Amgen | $229.9B | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)NCT05361395Number of Participants with a Dose Limiting Toxicity (DLT) | Phase 1 | Active, not recruiting | Drug: Tarlatamab, Carboplatin, Etoposide, Atezolizumab, Durvalumab | Extensive Stage Small Cell Lung Cancer | 184 | 2022-08-24 | 2028-08-28 | in 739 d | 2026-03-03 |
| GLUE | Monte Rosa Therapeutics, Inc | $1.3B | Study of Oral MRT-2359 in Selected Cancer PatientsNCT05546268Phase 1 Evaluates safety and tolerability of MRT-2359 over a 28-day cycle by the occurrence and frequency of dose limiting toxicities (DLTs) for determination of the MTD and/or RP2D | Phase 1/2 | Active, not recruiting | Drug: Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359 | NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer | 174 | 2022-10-12 | May 2026 | — | 2026-03-03 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)NCT04894591observationalOverall Response Rate (ORR) | — | Completed | Drug: Zepzelca | Extensive-stage Small-cell Lung Cancer | 272 | 2021-06-28 | 2025-06-04actual | — | 2026-02-27 |
| 4568.T | Daiichi Sankyo | $31.7B | Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)NCT05280470Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC | Phase 2 | Active, not recruiting | Drug: Ifinatamab Deruxtecan (I-DXd) | Extensive-stage Small-cell Lung Cancer | 187 | 2022-03-09 | 2025-03-03actual | — | 2026-02-25 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsNCT06305962Time Activity Curves (TACs) | Early Phase 1 | Recruiting | Drug: 177Lu-RAD204 | PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer, Cutaneous Melanoma, HNSCC, Endometrial Cancer, Mmr Deficiency, MSI-High | 30 | 2024-06-03 | Dec 2027 | ≤ 498 d | 2026-02-19 |
| MGNX | MacroGenics | $261M | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117results2026-02-09Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator | Phase 2 | Terminatedsponsor's stated reason: Business reasons | Biological: vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine · Drug: Abiraterone, Enzalutamide | Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma | 192 | 2023-06-13 | 2024-07-04actual | — | 2026-02-09 |
| 4519.T | Chugai Pharmaceutical | $72.4B | A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCERNCT07107490All part : Adverse events of ALPS12[safety and tolerability] | Phase 1 | Recruiting | Drug: ALPS12, obinutuzumab | Extensive Stage Small Cell Lung Cancer | 122 | 2025-10-08 | 2028-09-30 | in 772 d | 2026-02-06 |
| ABBV | AbbVie | $457.5B | Expanded Access to ABBV-706NCT07310277expanded access | — | Available | Drug: ABBV-706 | Small Cell Lung Cancer | — | — | — | — | 2026-01-29 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. | Phase 2 | Active, not recruiting | Drug: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | 40 | 2018-12-11 | 2029-08-31 | in 1,107 d | 2026-01-14 |
| AMGN | Amgen | $229.9B | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerNCT05740566results2026-01-05Overall Survival (OS) | Phase 3 | Active, not recruiting | Drug: Tarlatamab, Lurbinectedin, Topotecan, Amrubicin | Small Cell Lung Cancer (SCLC) | 509 | 2023-05-31 | 2025-01-29actual | — | 2026-01-05 |
| AMGN | Amgen | $229.9B | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabNCT06211036OS | Phase 3 | Active, not recruiting | Drug: Tarlatamab, Durvalumab | Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer | 563 | 2024-06-05 | 2027-07-05 | in 319 d | 2025-12-17 |
| AZN | AstraZeneca | — | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT03703297results2025-08-01Durvalumab Versus Placebo: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 | Phase 3 | Active, not recruiting | Drug: Durvalumab, Tremelimumab · Other: Placebo | Small Cell Lung Cancer | 730 | 2018-09-27 | 2024-01-15actual | — | 2025-11-21 |
| AMGN | Amgen | $229.9B | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)NCT03319940Number of participants with dose limiting toxicities (DLT) for all indications | Phase 1 | Active, not recruiting | Drug: Tarlatamab, Pembrolizumab, CRS Mitigation Strategies | Small Cell Lung Carcinoma | 269 | 2017-12-26 | 2026-12-31 | in 133 d | 2025-11-19 |
| INCY | Incyte Corporation | $24.7B | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsNCT04272034Number of treatment-emergent adverse events | Phase 1 | Terminatedsponsor's stated reason: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision. | Drug: INCB099318 | Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, Basal Cell Carcinoma (Unresectable or Metastatic), Sarcomatoid Renal Cell Carcinoma, Clear Cell Ovarian or Endometrial Carcinoma, Anal Carcinoma, Squamous Cell Penile Carcinoma, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L) | 105 | 2021-03-26 | 2024-08-16actual | — | 2025-10-16 |
| AMGN | Amgen | $229.9B | A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLCNCT03392064Incidence of dose limiting toxicities (DLTs) | Phase 1 | Suspendedsponsor's stated reason: Study on enrollment hold, may potentially resume. No active subjects on trial. | Biological: AMG 119 | Small Cell Lung Cancer | 6 | 2018-09-10 | 2028-01-14 | in 512 d | 2025-10-15 |
| AMGN | Amgen | $229.9B | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)NCT04885998results2024-10-15Part 1: Number of Participants Who Experienced Dose-limiting Toxicity (DLT) | Phase 1 | Completed | Drug: Tarlatamab, AMG 404 | Small Cell Lung Cancer | 23 | 2021-09-27 | 2023-07-12actual | — | 2025-09-29 |
| INCY | Incyte Corporation | $24.7B | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsNCT04242199Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: INCB099280 | Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma | 182 | 2020-09-04 | 2024-08-29actual | — | 2025-07-14 |
| AZN | AstraZeneca | — | REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCERNCT06826677observationalOverall survival | — | Completed | Drug: Durvalumab | Small Cell Lung Carcinoma | 71 | 2024-07-30 | 2025-01-23actual | — | 2025-06-24 |
| AZN | AstraZeneca | — | Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung CancerNCT04774380results2024-08-20Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs) | Phase 3 | Completed | Drug: Durvalumab, Cisplatin, Carboplatin, Etoposide | Extensive-stage Small Cell Lung Cancer | 152 | 2021-11-11 | 2023-06-12actual | — | 2025-05-23 |
| AZN | AstraZeneca | — | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung CancerNCT04870112Observed serum concentration (Ctrough) | Phase 1 | Terminatedsponsor's stated reason: AstraZeneca has decided to stop further enrollment and the study was terminated when all patients in Part 1 completed their last study visit. No safety issues or clinical concerns however, have been identified for this study. Part 2 was not initiated | Drug: Durvalumab, Cisplatin, Carboplatin, Etoposide | Non-Small Cell Lung Cancer, Small Cell Lung Cancer | 18 | 2021-06-28 | 2023-08-30actual | — | 2025-04-17 |
| BNTX | BioNTech SE | — | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411NCT04101357results2025-03-18Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BNT411, Atezolizumab, Carboplatin, Etoposide | Solid Tumor, Extensive-stage Small Cell Lung Cancer | 54 | 2020-06-19 | 2024-01-19actual | — | 2025-03-18 |
| AMGN | Amgen | $229.9B | Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung CancerNCT06064500expanded access | — | Approved for marketing | Drug: Tarlatamab | Small Cell Lung Cancer | — | — | — | — | 2025-03-10 |
| IPN.PA | Ipsen | $15.5B | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung CancerNCT03088813results2023-10-17Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Phase 3 | Completed | Drug: Irinotecan liposome injection, Topotecan | Small Cell Lung Cancer | 491 | 2018-04-25 | 2022-02-08actual | — | 2025-02-19 |
| AZN | AstraZeneca | — | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsNCT03509012Number of subjects with Dose Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: Durvalumab, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, Cisplatin (dose level 1), Cisplatin (dose level 2) · Radiation: External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), External beam radiation (standard) | Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma | 105 | 2018-05-02 | 2020-12-31actual | — | 2025-01-14 |
| AZN | AstraZeneca | — | Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung CancerNCT04712903results2025-01-07Number of Patients With Adverse Events (AEs) Grade ≥ 3 | Phase 3 | Completed | Drug: Durvalumab, Cisplatin, Etoposide, Carboplatin | Small Cell Lung Carcinoma Extensive Disease | 101 | 2020-12-16 | 2023-06-21actual | — | 2025-01-07 |
| AZN | AstraZeneca | — | A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in BrazilNCT06008353observationalDemographic Characteristics of the Cohort | — | Active, not recruiting | Other: Observational study | Extensive-stage Small-cell Lung Cancer | 60 | 2024-01-18 | 2026-08-31 | in 11 d | 2024-12-19 |
| AZN | AstraZeneca | — | Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)NCT04449861results2024-11-27Percentage of Participants With Grade ≥3 AEs | Phase 3 | Completed | Drug: Durvalumab plus chemotherapy | Small Cell Lung Carcinoma Extensive Disease | 166 | 2020-12-07 | 2023-03-30actual | — | 2024-11-27 |
| SLS | Sellas Life Sciences Group | $2.6B | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersNCT03761914results2024-11-19Overall Response Rate (ORR) - Best Overall Response | Phase 1/2 | Completed | Biological: galinpepimut-S, pembrolizumab, GM-CSF · Other: Montanide | Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer | 26 | 2019-09-30 | 2022-07-05actual | — | 2024-11-19 |
| AZN | AstraZeneca | — | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursNCT04504669Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of AEs and SAEs | Phase 1 | Completed | Drug: AZD8701 · Biological: Durvalumab | Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours | 60 | 2020-08-18 | 2024-10-07actual | — | 2024-11-05 |
| BMY | Bristol-Myers Squibb | $134.9B | Trial of BMS-986012 in Combination With Platinum and EtoposideNCT02815592Number of participants with adverse events (AEs) | Phase 1 | Completed | Drug: BMS-986012, Cisplatin, Etoposide, Platinum, Carboplatin | Small Cell Lung Cancer | 12 | 2016-11-28 | 2019-12-15actual | — | 2024-09-04 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398Treatment-related adverse events as assessed by CTCAE v4.03 | Phase 1 | Completed | Biological: XmAb®23104, Yervoy® (ipilimumab) | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma | 198 | 2019-05-01 | 2024-02-15actual | — | 2024-07-05 |
| 4519.T | Chugai Pharmaceutical | $72.4B | Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)NCT04501497observational12 months survival rate | — | Completed | — | Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer | 1,221 | 2020-08-21 | 2023-02-03actual | — | 2024-04-02 |
| 4519.T | Chugai Pharmaceutical | $72.4B | The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)NCT04818983observationalCorrelation between PD-L1 SNP and atezolizumab combination therapy | — | Completed | — | Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer | 470 | 2021-04-07 | 2023-02-03actual | — | 2024-04-02 |
| BMY | Bristol-Myers Squibb | $134.9B | BMS-986012 in Relapsed/Refractory SCLCNCT02247349results2024-03-05Number of Participants With Adverse Events (AEs) | Phase 1/2 | Completed | Biological: BMS-986012 (anti-fucosyl-GM1), Nivolumab | Small Cell Lung Cancer | 106 | 2014-11-14 | 2022-12-21actual | — | 2024-03-05 |
| ABBV | AbbVie | $457.5B | A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung CancerNCT03639194Number of Participants With Adverse Events | Phase 1 | Completed | Drug: ABBV-011, Budigalimab | Small Cell Lung Cancer | 132 | 2018-10-24 | 2024-01-25actual | — | 2024-02-09 |
| MGNX | MacroGenics | $261M | A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsNCT03219268Number of participants with Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy) | Phase 1 | Completed | Biological: tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab | Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer | 277 | 2017-08-18 | 2023-02-08actual | — | 2023-12-21 |
| FATE | Fate Therapeutics | $307M | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyNCT04106167observationalOverall Survival (OS) post-Infusion | — | Terminatedsponsor's stated reason: This study was terminated by the Sponsor. | Genetic: Allogeneic natural killer (NK) cell | Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma | 20 | 2019-06-11 | 2023-08-11actual | — | 2023-09-21 |
| FATE | Fate Therapeutics | $307M | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsNCT03841110The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort. | Phase 1 | Completed | Drug: FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2 | Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma | 37 | 2019-02-15 | 2022-11-15actual | — | 2023-05-01 |
| XNCR | Xencor, Inc. | $1.9B | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung CancerNCT04590781results2023-04-20Number of Participants With Treatment-emergent Adverse Events | Phase 1/2 | Terminatedsponsor's stated reason: The study has been terminated early by the sponsor due to business decision. | Biological: XmAb18087 · Drug: XmAb18087 ± Pembrolizumab | Merkel Cell Carcinoma, Small Cell Lung Cancer | 4 | 2021-05-10 | 2022-03-24actual | — | 2023-04-20 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. | Phase 1 | Completed | Biological: XmAb®22841, Pembrolizumab (Keytruda®) | Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma | 78 | 2019-05-29 | 2023-02-16actual | — | 2023-03-30 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsNCT03517488Determine the safety and tolerability profile of XmAb20717 | Phase 1 | Completed | Biological: XmAb20717 | Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma | 150 | 2018-07-10 | 2022-06-01actual | — | 2022-12-01 |
| GOSS | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | $70M | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaNCT04060342Phase 1 Dose Escalation - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Drug: GB1275, nab-paclitaxel and gemcitabine, pembrolizumab | Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma | 61 | 2019-08-13 | 2022-04-11actual | — | 2022-08-18 |
| AAPG | Ascentage Pharma Group Inc. | — | A Study of APG-1252 in Patients With SCLC or Other Solid TumorsNCT03080311Dose limiting toxicity (DLT) determination | Phase 1 | Completed | Drug: APG-1252 | Small Cell Lung Cancer, Solid Tumor | 50 | 2017-02-12 | 2020-06-22actual | — | 2022-07-12 |
| AAPG | Ascentage Pharma Group Inc. | — | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung CancerNCT04210037Primary Toxicity Endpoint: dose-limiting toxicity (DLT) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: APG-1252, Paclitaxel | Small Cell Lung Cancer | 28 | 2020-08-20 | 2021-08-30actual | — | 2022-07-12 |
| INCY | Incyte Corporation | $24.7B | A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesNCT03652077Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: INCAGN02390 | Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency | 40 | 2018-09-24 | 2021-08-18actual | — | 2021-11-15 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerNCT01631552results2021-04-06Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events | Phase 1/2 | Completed | Drug: Sacituzumab Govitecan-hziy (SG) | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | 515 | 2012-12-17 | 2019-03-01actual | — | 2021-08-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung CancerNCT03898791Number of Participants with Dose Reductions | Phase 1 | Completed | Drug: LY3295668 Erbumine | Small Cell Lung Cancer | 48 | 2019-07-16 | 2020-06-02actual | — | 2021-08-05 |
| ABBV | AbbVie | $457.5B | A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung CancerNCT03086239Number of participants with dose-limiting toxicities (DLT) | Phase 1 | Completed | Drug: Rovalpituzumab tesirine | Small Cell Lung Cancer | 29 | 2017-04-28 | 2018-01-30actual | — | 2021-08-03 |
| ABBV | AbbVie | $457.5B | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung CancerNCT02674568results2019-10-23Objective Response Rate | Phase 2 | Completed | Drug: Rovalpituzumab tesirine | Small Cell Lung Cancer | 342 | 2016-01-25 | 2018-10-19actual | — | 2021-07-30 |
| ABBV | AbbVie | $457.5B | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)NCT03033511results2020-12-21Overall Survival (OS) in Participants With Extensive-Stage Small Cell Lung Cancer With Delta-Like Protein 3 High Expression in Tumor (DLL3high) | Phase 3 | Terminatedsponsor's stated reason: Independent Data Monitoring Committee recommendation | Drug: Placebo for dexamethasone, Placebo for rovalpituzumab tesirine, Rovalpituzumab tesirine, Dexamethasone | Small Cell Lung Cancer | 748 | 2017-02-07 | 2019-11-20actual | — | 2021-07-29 |
| LLY | Eli Lilly and Company | $1.15T | A Study of AK-01 (LY3295668) in Solid TumorsNCT03092934results2021-07-02Phase 1: Maximum Tolerated Dose | Phase 1/2 | Completed | Drug: LY3295668 | Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms, Head and Neck Neoplasms, Breast Neoplasms, Solid Tumor, Adult, Small Cell Lung Carcinoma | 13 | 2017-05-29 | 2020-04-20actual | — | 2021-07-02 |
| ABBV | AbbVie | $457.5B | Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)NCT03061812results2021-02-23Overall Survival (OS) | Phase 3 | Completed | Drug: Rovalpituzumab tesirine, Topotecan, Dexamethasone | Small Cell Lung Cancer | 444 | 2017-04-11 | 2020-02-12actual | — | 2021-02-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Small Cell Lung Cancer is matched — 14 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Small Cell Lung Cancer
- Small Cell Lung Carcinoma
- Small-cell Lung Cancer
- Extensive-stage Small-cell Lung Cancer
- SCLC
- Small Cell Lung Cancer (SCLC)
- Extensive Stage Small Cell Lung Cancer
- Extensive-stage Small Cell Lung Cancer
- Small Cell Lung Cancer ( SCLC )
- Small Cell Lung Carcinoma Extensive Disease
- Carcinoma, Small Cell Lung
- Extensive Disease Small Cell Lung Cancer
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Relapsed/Refractory Small Cell Lung Cancer
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Small Cell Lung Cancer” (a text search, wider than this page)